Analysis Group Vice President Ted Davis to Speak at The Knowledge Group’s Antitrust Enforcement for Pay-For-Delay Settlements: U.S. and E.U. Perspective
New York, NY, June 15, 2016 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Analysis Group Vice President Ted Davis will speak at the Knowledge Group’s webcast entitled: “Antitrust Enforcement for Pay-For-Delay Settlements: U.S. and E.U. Perspective.” This event is scheduled for October 20, 2016 from 12:00pm – 2:00pm (ET).
For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=1730
About Ted Davis
Analysis Group Vice President Ted Davis specializes in the application of financial economics and data analysis to litigation and other complex business situations. His research has investigated issues related to intellectual property and patents, antitrust law, industrial organization, asset prices and financial market infrastructure. He is a CFA (Chartered Financial Analyst) charterholder.
Mr. Davis has managed case teams and supported testifying experts through all phases of complex business litigation, including fact and expert discovery, class certification, liability and damages, and trial. Mr. Davis has supported testifying experts in a variety of cases related to pharmaceutical markets, including antitrust cases involving allegations of delayed generic entry and settlements of patent litigation between brand and generic manufacturers.
About Analysis Group
Since 1981, Analysis Group has provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, global health care corporations, and government agencies. Our work is grounded in a collaborative approach that allows us to effectively integrate the best ideas from leading academic and industry experts with our more than 600 professionals. As a result, our clients receive thoughtful, pragmatic solutions to their most challenging business and litigation problems. Through our work in thousands of cases across multiple industries, we have become one of the largest economics consulting firms in North America, with 11 offices in the United States, Canada, and China.
Event Synopsis:
Reverse payment settlements, also referred to as pay-for-delay agreements, describe a settlement of patent infringement litigation between a branded pharmaceutical company and generic in which payment is received by the generic from the branded pharmaceutical company. In typical patent infringement litigation settlement, the alleged infringer pays the patent holder. In a reverse payment settlement, the reverse occurs.
Further, in recent years, these agreements have caused considerable argument within the pharma industry of both the United States and the European Union. Antitrust agencies and courts are making conflicting conclusions regarding the agreements’ conformity with competition rules.
The fundamental question is whether any particular reverse payment settlement includes payment by the incumbent firm to keep a competitor out of the market (pay for delay) or compensation that is competitively benign. Since the Supreme Court’s decision in Actavis, district courts have been attempting to follow a rule-of-reason approach described by the decision. However, considerable disagreement persists about what aspects of these settlements may demonstrate that a deal is anticompetitive or not.
In this Live Webcast, a notable panel of thought leaders and professionals assembled by The Knowledge Group will provide the audience with an in-depth analysis of the fundamentals as well as recent developments with regards to the Antitrust Enforcement for Reverse Payment Settlements in the United States and European Union landscape.
Key topics include:
- Reverse Payment Settlements – A Legal Primer
- “By Object” Vs. “By Effect” Infringements
- Recent Challenges of Patent Settlements
- Identifying and Mitigating Risks
- Antitrust Enforcement Priorities
- Reverse Payment Agreements: Costs and Damages
- Role of No Authorized Generic Clauses and Ancillary Agreements
- Scope and Limitations
- Recent Legal Issues and Insights Antitrust Lawyers
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=1730
About Ted Davis
Analysis Group Vice President Ted Davis specializes in the application of financial economics and data analysis to litigation and other complex business situations. His research has investigated issues related to intellectual property and patents, antitrust law, industrial organization, asset prices and financial market infrastructure. He is a CFA (Chartered Financial Analyst) charterholder.
Mr. Davis has managed case teams and supported testifying experts through all phases of complex business litigation, including fact and expert discovery, class certification, liability and damages, and trial. Mr. Davis has supported testifying experts in a variety of cases related to pharmaceutical markets, including antitrust cases involving allegations of delayed generic entry and settlements of patent litigation between brand and generic manufacturers.
About Analysis Group
Since 1981, Analysis Group has provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, global health care corporations, and government agencies. Our work is grounded in a collaborative approach that allows us to effectively integrate the best ideas from leading academic and industry experts with our more than 600 professionals. As a result, our clients receive thoughtful, pragmatic solutions to their most challenging business and litigation problems. Through our work in thousands of cases across multiple industries, we have become one of the largest economics consulting firms in North America, with 11 offices in the United States, Canada, and China.
Event Synopsis:
Reverse payment settlements, also referred to as pay-for-delay agreements, describe a settlement of patent infringement litigation between a branded pharmaceutical company and generic in which payment is received by the generic from the branded pharmaceutical company. In typical patent infringement litigation settlement, the alleged infringer pays the patent holder. In a reverse payment settlement, the reverse occurs.
Further, in recent years, these agreements have caused considerable argument within the pharma industry of both the United States and the European Union. Antitrust agencies and courts are making conflicting conclusions regarding the agreements’ conformity with competition rules.
The fundamental question is whether any particular reverse payment settlement includes payment by the incumbent firm to keep a competitor out of the market (pay for delay) or compensation that is competitively benign. Since the Supreme Court’s decision in Actavis, district courts have been attempting to follow a rule-of-reason approach described by the decision. However, considerable disagreement persists about what aspects of these settlements may demonstrate that a deal is anticompetitive or not.
In this Live Webcast, a notable panel of thought leaders and professionals assembled by The Knowledge Group will provide the audience with an in-depth analysis of the fundamentals as well as recent developments with regards to the Antitrust Enforcement for Reverse Payment Settlements in the United States and European Union landscape.
Key topics include:
- Reverse Payment Settlements – A Legal Primer
- “By Object” Vs. “By Effect” Infringements
- Recent Challenges of Patent Settlements
- Identifying and Mitigating Risks
- Antitrust Enforcement Priorities
- Reverse Payment Agreements: Costs and Damages
- Role of No Authorized Generic Clauses and Ancillary Agreements
- Scope and Limitations
- Recent Legal Issues and Insights Antitrust Lawyers
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories